Poplar Therapeutics
Developing a new class of anti-IgE therapy to treat food allergy and other atopic conditions
$45MSeries A+
Role not disclosedLoading investors…
Activity from announced rounds
Developing a new class of anti-IgE therapy to treat food allergy and other atopic conditions